Novartis gets FDA warning about Austrian plant
This article was originally published in Scrip
Novartis's Sandoz unit needs to get its Austrian Unterach plant in order after a US FDA warning letter detailed a number of violations, including the manufacturing and distribution of "unapprovable" finished drugs in the US.
You may also be interested in...
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.